The Dutch biotech sector is hot. Successful drug developments and acquisitions are common practise. Crucell and Galapagos are well known Dutch businesses in this sector. Recently several mega-deals have reached the press such as the take-over of Acerta by AstraZeneca. Even early stage ventures like Dezima end up in the hands of large corporate players. We often read the headlines about Dutch success in biotech, however; most of us lack the insight to understand how unique and often complex it is to go from idea to (public)market access.
The Finance Circle is proud to have been able to invite three key players and alumni of Nyenrode to share their views from their specific areas of expertise, namely:
1. Sander Slootweg - Managing Partner Forbion Capital Partners (alumnus BBA 1986, 19860081), Forbion Capital Partners, with € 700 million AUM one of the largest Biotech investors.
2. Bart Filius – CFO Galapagos (alumnus BBA 1988, 19880056), Galapagos, specialized in the discovery and development of small molecule medicines with novel modes of action, and listed on the Amsterdam Stock Exchange.
3. Marco de Boer – CEO Ntrans Technologies (alumnus EMBA 2016), Ntrans Technologies markets intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences
For the resumés of our speakers, click here.
This NA VCV Kring Finance event will be interactive and offers a platform for sharing ideas and networking.
Location: De Industriëele Groote Club Amsterdam
VCV members: € 25
Others: € 30
Please confirm your presence and pay via this site:
We hope to have attracted your interest with this program and look forward to seeing you June 20th in Amsterdam!
Nyenrode Alumni Kring Finance